|
Sep 30
|
Neffy nasal spray: a game changer for asthma patients and epinephrine delivery?
|
|
Aug 27
|
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED)
|
|
Aug 26
|
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
|
|
Jul 25
|
US Growth Companies With Insider Ownership As High As 31%
|
|
Jun 26
|
US Growth Companies With High Insider Ownership To Watch
|
|
Jun 24
|
Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY),
|
|
May 28
|
Top US Growth Companies With High Insider Ownership To Watch In May 2024
|
|
May 13
|
ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...
|
|
May 11
|
ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)
|
|
May 9
|
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
|
|
Apr 30
|
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
|
|
Apr 5
|
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
|
Apr 3
|
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
|
|
Apr 3
|
Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
|
|
Apr 1
|
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
|
|
Mar 26
|
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
|
|
Mar 21
|
ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results
|
|
Mar 21
|
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 15
|
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
|
|
Mar 7
|
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
|